By Business/Source
Currency:USD
2023/FY
Stock NameRevenueRatio
Development of biopharmaceutical products for the treatment of patients with inflammatory bowel disease 886K100.00%
By Country/Region
Currency:USD
2023/FY
Stock NameRevenueRatio
United States886K100.00%